Drug profile · INN
emapalumab
GAMIFANT
emapalumab (GAMIFANT) is a interferon gamma inhibitor.
EMA: refused Antineoplastic and immunomodulating agents (L04) L04AA39
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — emapalumab
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.83
Quick answer
emapalumab (GAMIFANT) is a interferon gamma inhibitor.
Key facts
INN emapalumab
Brand GAMIFANT
Mechanism Interferon gamma inhibitor
Target Interferon gamma
Therapeutic class Antineoplastic and immunomodulating agents (L04)
ATC code L04AA39
Mechanism of action
Interferon gamma inhibitor
Primary target: Interferon gamma
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | refused | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is emapalumab?
emapalumab (GAMIFANT) is a interferon gamma inhibitor.
What is the brand name for emapalumab?
GAMIFANT is a marketed brand name for emapalumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.